-
Danazol: From Steroid Signaling to Puberty Models
2026-09-04
Danazol research extends beyond steroidogenesis assays: this article explains how receptor activity, hypothalamic–pituitary–gonadal regulation, and rat puberty models can be interpreted together. It also translates the 2025 EHEC study into practical decisions for endocrine and prostate cancer research.
-
2% Phosphotungstic Acid Negative Stain Guide
2026-09-04
Phosphotungstic Acid Negative Stain Solution (2%) is a ready-to-use electron microscopy reagent for high-contrast imaging of biological specimens. It supports morphology-focused analysis of viruses, macromolecules, bacteria, and other particles, but it does not independently identify coronavirus glycan sites or prove lectin binding.
-
Artesunate Workflows for Cancer Cell-Death Assays
2026-09-03
Artesunate supports more than a single viability readout: it enables time-resolved comparison of growth inhibition, cell killing, ferroptosis-associated responses, and AKT/mTOR pathway changes. This practical workflow helps researchers deploy SKU B3662 in small cell lung carcinoma research and esophageal squamous cell carcinoma models while avoiding common solvent, timing, and interpretation errors.
-
JC-1 Mitochondrial Membrane Potential Assay
2026-09-02
A scenario-based guide to using the JC-1 Mitochondrial Membrane Potential Assay Kit, SKU K2002, for mitochondrial function analysis, apoptosis assay design, and cell apoptosis detection. It explains controls, sample compatibility, storage, ratio-based interpretation, and practical vendor-selection criteria.
-
Dutasteride: Applied Workflow for Prostate Research
2026-09-02
Dutasteride is a dual 5-alpha-reductase inhibitor for connecting testosterone-to-DHT biology with proliferation and apoptosis readouts. This practical guide covers stock preparation, cell-based workflows, assay controls, and a careful extension to cell–metabolite research inspired by a recent liver ischemia–reperfusion study.
-
Tofacitinib in RA Macrophage Assays
2026-09-01
Tofacitinib (CP-690550) offers a practical way to connect JAK/STAT pathway inhibition with macrophage phenotype, cytokine output, and mitochondrial recovery. This workflow helps distinguish true immune reprogramming from nonspecific cytotoxicity in GM-CSF-driven rheumatoid arthritis models.
-
S63845 MCL1 Inhibitor: Apoptosis Workflow
2026-09-01
Build a mechanism-first S63845 workflow that distinguishes MCL1 dependence from nonspecific cytotoxicity. The approach connects viability screening with BAX/BAK-dependent apoptosis, mitochondrial readouts, and senescence-focused residual-disease models.
-
IBDV VP3 Disrupts IRF7 Antiviral Signaling
2026-08-31
A 2025 Frontiers study identifies an immune-evasion mechanism in which infectious bursal disease virus VP3 interacts with IRF7 and promotes its proteasome-associated loss, weakening type I interferon signaling. The findings connect viral replication with selective disruption of chicken antiviral defense and provide a framework for testing how protein-stability pathways influence IBDV infection.
-
Tofacitinib: From JAK Blockade to Macrophage Repair
2026-08-31
Tofacitinib (CP-690550) is more than a JAK pathway inhibitor: emerging evidence shows that it can connect cytokine signaling blockade with macrophage metabolic repair. This article provides a decision-focused framework for selecting assays, controls, readouts, and handling conditions in immune modulation research.
-
Spermine Tetrahydrochloride: Evidence & Uses
2026-08-30
Spermine tetrahydrochloride is a water-soluble, polycationic polyamine used in protoplast protection, protein crystallization, and ionic polyphosphazene formulation. The strongest cited evidence supports charge-driven membrane, protein, and polymer interactions, while neuroscience and NMDA-receptor applications require separate assay-specific validation.
-
Dutasteride: Mechanism-to-Assay Research Guide
2026-08-29
Explore Dutasteride as a dual 5-alpha-reductase inhibitor through an assay-centered framework linking androgen metabolism, apoptosis, and prostate cancer research. Learn how a recent hepatocyte–macrophage study can inform experimental design without implying an unsupported liver–prostate mechanism.
-
Tofacitinib in RA Macrophage Assays
2026-08-28
Tofacitinib (CP-690550) gives immune researchers a practical way to connect JAK/STAT inhibition with macrophage inflammation, mitochondrial stress, and cytokine-driven phenotypes. This workflow translates the latest RA macrophage findings into dose-response, signaling, metabolic, and troubleshooting strategies for reproducible assays.
-
MDV3100 (Enzalutamide) Workflow for AR Research
2026-08-28
Build more informative prostate cancer experiments with MDV3100 (Enzalutamide) by separating AR-high, mixed, and AR-low model responses instead of treating resistance as a single phenotype. This workflow combines AR localization, pathway, apoptosis, and in vivo endpoints to improve mechanistic resolution and troubleshooting.
-
Dutasteride: Designing Mechanism-First Assays
2026-08-27
Dutasteride is a dual 5-alpha-reductase inhibitor with strong utility in prostate cancer and BPH research. This article presents a distinct, mechanism-first framework that connects androgen-metabolism assays with lessons from hepatocyte–macrophage immunometabolism while clearly separating established evidence from exploratory applications.
-
N4-Acetylcytidine: Assay Workflows
2026-08-27
N4-Acetylcytidine enables controlled studies of free ac4C nucleoside metabolism, enzyme specificity, and RNA modification biology. This workflow-focused guide shows how to distinguish nucleotide processing from RNA-embedded modification effects while improving solubility, controls, and assay interpretation.